Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning

被引:33
|
作者
Ganti, Apar Kishor [1 ]
Lee, Stephanie J.
Vose, Julie M.
Devetten, Marcel P.
Bociek, R. Gregory
Armitage, James O.
Bierman, Philip J.
Maness, Lori J.
Reed, Elizabeth C.
Loberiza, Fausto R., Jr.
机构
[1] Univ Nebraska Med Ctr, Hematol Oncol Sect, Dept Internal Med, Omaha, NE 68198 USA
关键词
D O I
10.1200/JCO.2007.11.1914
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Engagement in advance care planning (ACP) is viewed as a way to prepare for possible death. In patients undergoing hematopoietic stem-cell transplantation (HSCT), an aggressive but possibly curative procedure for cancer, encouraging engagement in ACP is difficult. We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes. Patients and Methods Adult patients who were undergoing their first HSCT for hematologic malignancies between 2001 and 2003 were included. ACP was defined as having a living will, a power of attorney for health care, or life-support instructions. Outcomes assessed included the length of hospital stay, in-hospital mortality, and overall survival. Results Of the 343 patients, 172 did not have ACP, whereas 171 did have ACP, and 127 of those were reviewable. Of those with reviewable ACP, 28 patients (22%) completed ACP before cancer diagnosis, 87 (68%) completed ACP after the cancer diagnosis but before HSCT, and 12 (10%) engaged in ACP after HSCT. Patients without ACP before HSCT had a significantly greater risk of death compared with patients with ACP (hazard ratio, 2.11; 95% CI, 1.34 to 3.33; P = .001) while adjusting for statistically significant factors. Conclusion Our study demonstrated that lack of engagement in ACP is associated with adverse outcomes after HSCT. Thus, the patients least likely to have planned for poor outcomes are the ones most likely to face them. Additional studies should evaluate the nature of this association and should seek modifiable explanatory factors that could be the target of interventions.
引用
下载
收藏
页码:5643 / 5648
页数:6
相关论文
共 50 条
  • [31] Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation
    Sala-Torra, O
    Hanna, C
    Loken, MR
    Flowers, MED
    Maris, M
    Ladne, PA
    Mason, JR
    Senitzer, D
    Rodriguez, R
    Forman, SJ
    Deeg, HJ
    Radich, JP
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (05) : 511 - 517
  • [32] Outcomes of Patients Older Than Age 70 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
    Brunner, Andrew M.
    Chen, Yi-Bin
    Kim, Haesook
    Coughlin, Erin
    Alyea, Edwin P., III
    Armand, Philippe
    Ballen, Karen
    Cutler, Corey
    Dey, Bimalangshu R.
    Glotzbecker, Brett
    Koreth, John
    McAfee, Steven L.
    Spitzer, Thomas R.
    Soiffer, Robert J.
    Antin, Joseph H.
    Ho, Vincent T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S114 - S114
  • [33] Day+100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies
    Moneib, Hisham
    Hafez, Hanafy
    Abdalla, Amr
    Hassanain, Omneya
    Lehmann, Leslie
    el Haddad, Alaa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : E221 - E227
  • [34] Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation
    Shah, Nirali N.
    Borowitz, Michael J.
    Robey, Nancy
    Gamper, Christopher
    Symons, Heather J.
    Loeb, David
    Wayne, Alan S.
    Chen, Allen R.
    BLOOD, 2012, 120 (21)
  • [35] Advance care planning and specialty palliative care utilization for patients with hematologic malignancies who undergo allogeneic hematopoietic cell transplant.
    Schoenbeck, Kelly L.
    McNey, Lisa M.
    Eckhert, Erik
    Galligan, Derek
    Mannis, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [36] HEMATOPOIETIC RECONSTITUTION AFTER AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH MALIGNANCIES - A MULTICENTER RETROSPECTIVE STUDY
    PIERELLI, L
    IACONE, A
    QUAGLIETTA, AM
    NICOLUCCI, A
    MENICHELLA, G
    PANICI, PB
    DANTONIO, D
    DELAURENZI, A
    DEROSA, L
    FIORITONI, G
    INDOVINA, A
    LEONE, G
    MAJOLINO, I
    MONTUORO, A
    SCIME, R
    TORLONTANO, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (01) : 70 - 75
  • [37] Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies
    Gürman, G
    Arat, M
    Ilhan, O
    Konuk, N
    Beksaç, M
    Çelebi, H
    Özcan, M
    Arslan, Ö
    Üstün, C
    Akan, H
    Uysal, A
    Koç, H
    CYTOTHERAPY, 2001, 3 (04) : 253 - 260
  • [38] Recovery after stem-cell transplantation for hematologic diseases
    Lee, SJ
    Fairclough, D
    Parsons, SK
    Soiffer, RJ
    Fisher, DC
    Schlossman, RL
    Antin, JH
    Weeks, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 242 - 252
  • [39] The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age
    Dong, Lujia
    Wu, Tong
    Gao, Zhi-Yong
    Zhang, Mei-Jie
    Kan, Fangyu
    Spellman, Stephen R.
    Tan, Xi-You
    Zhao, Yan-Li
    Wang, Jing-Bo
    Lu, Dao-Pei
    Miklos, David
    Petersdorf, Effie
    Fernandez-Vina, Marcelo
    Lee, Stephanie J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (08) : 1205 - 1213
  • [40] Nontuberculous mycobacterial infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation
    El Zein, Said
    Mendoza, Maria A.
    Wilson, John W.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25